20
Nov2019
14
Nov2019
Business Wire article link: Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa
Highlights:
Trial meets its Primary Endpoint with 39% ORR (95%CI 22%-58%) in patients with advanced PEComa – a rare sarcoma with no currently approved therapy
First prospective clinical study in advanced ... Read More
November 14, 2019admin
14
Nov2019
20
Jun2019
03
Jun2019
Business Wire article link: Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa
June, 3 2019, Aadi Bioscience, Inc. (Aadi), Aadi Bioscience, Inc (Aadi), a privately held clinical stage biopharmaceutical company, today released preliminary data on the ongoing nab-sirolimus (ABI-009) registration trial (AMPECT) for Advanced ... Read More
June 3, 2019admin